Asset profile
Orticumab
Monoclonal antibody
Evidence outlook · lead readout
NCT01258907 · Atherosclerosis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT01258907: The study randomized 147 participants to two MLDL1278A regimens or placebo while maintaining stable statin therapy, with participants and investigators masked to treatment. Its primary endpoint was a surrogate imaging measure of plaque inflammation, and because results are not posted, it is not possible to determine whether the primary comparison was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
February 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.